S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
OTCMKTS:MRVFF

Nuvo Pharmaceuticals (MRVFF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free MRVFF Stock Alerts
$0.98
0.00 (0.00%)
(As of 03/16/2023)
Compare
Today's Range
$0.98
▼
$0.98
50-Day Range
$0.98
▼
$0.98
52-Week Range
$0.42
▼
$1.25
Volume
N/A
Average Volume
11,250 shs
Market Capitalization
$11.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
MRVFF stock logo

About Nuvo Pharmaceuticals Stock (OTCMKTS:MRVFF)

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

MRVFF Stock Price History

MRVFF Stock News Headlines

February 2, 2024 | morningstar.com
West Pharmaceutical Services Inc WST
August 1, 2023 | seekingalpha.com
NYMXF Nymox Pharmaceutical Corporation
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 10, 2023 | businesswire.com
Miravo Healthcare™ Obtains Final Order Approving Plan of Arrangement
February 24, 2023 | seekingalpha.com
MRVFF Nuvo Pharmaceuticals Inc.
February 21, 2023 | finance.yahoo.com
Miravo Healthcare™ Special Meeting Reminder
October 31, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces Third Quarter 2022 Results Release Date and Conference Call Details
August 2, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces Second Quarter 2022 Results Release Date and Conference Call Details
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
May 16, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces First Quarter 2022 Results
May 12, 2022 | stockhouse.com
Miravo Healthcare(TM) Provides an Update on the United States Pennsaid® 2% Business
May 12, 2022 | finance.yahoo.com
Miravo Healthcare™ Provides an Update on the United States Pennsaid® 2% Business
May 2, 2022 | stockhouse.com
Miravo Healthcare(TM) Announces First Quarter 2022 Results Release Date and Virtual Annual Meeting of Shareholders
May 2, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces First Quarter 2022 Results Release Date and Virtual Annual Meeting of Shareholders
April 19, 2022 | finance.yahoo.com
Miravo Healthcare™ to Present at Bloom Burton & Co. Healthcare Investor Conference
March 29, 2022 | seekingalpha.com
Nuvo Pharmaceuticals; reports Q4 results
March 28, 2022 | seekingalpha.com
Nuvo Pharmaceuticals Inc. 2021 Q4 - Results - Earnings Call Presentation
March 28, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces 2021 and Fourth Quarter Results
March 25, 2022 | stockhouse.com
Miravo Healthcare(TM) Acknowledged In The Globe and Mail's Third-Annual Women Lead Here Benchmark of Executive Gender Diversity
March 14, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces Fourth Quarter 2021 Results Release Date and Conference Call Details
March 1, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Older*
February 28, 2022 | stockhouse.com
Miravo Healthcare(TM) Announces Summary Judgment Ruling by the United States District Court for the District of New Jersey
February 28, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces Summary Judgment Ruling by the United States District Court for the District of New Jersey
February 28, 2022 | finance.yahoo.com
Miravo Healthcare(TM) to Present at Q1 Virtual Investor Summit
January 24, 2022 | finance.yahoo.com
Miravo Healthcare™ Named to 2022 OTCQX Best 50
January 18, 2022 | stockhouse.com
Miravo Healthcare(TM) Announces Participation at the H.C. Wainwright Bioconnect Conference
January 6, 2022 | finance.yahoo.com
Miravo Healthcare™ Announces Participation at the H.C. Wainwright Bioconnect Conference
See More Headlines
Receive MRVFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MRVFF
CUSIP
N/A
CIK
N/A
Web
www.nuvopharmaceuticals.com
Phone
(905) 673-6980
Fax
905-673-1842
Employees
100
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-25,700,000.00
Net Margins
20.88%
Pretax Margin
25.58%
Return on Equity
-1,996.22%
Return on Assets
14.25%

Debt

Debt-to-Equity Ratio
9.97
Current Ratio
2.11
Quick Ratio
1.77

Sales & Book Value

Annual Sales
$54.98 million
Price / Sales
0.20
Cash Flow
$0.09 per share
Price / Cash Flow
11.09
Book Value
($0.80) per share
Price / Book
-1.22

Miscellaneous

Outstanding Shares
11,400,000
Free Float
10,602,000
Market Cap
$11.17 million
Optionable
Not Optionable
Beta
0.98
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Jesse F. Ledger
    President & Chief Executive Officer
  • Bernard Chiasson
    Chief Scientific Officer & VP-Operations
  • Mary-Jane E. Burkett
    Chief Financial Officer & Vice President
  • Wade Hull
    Vice President-Research & Development
  • Katina K. Loucaides
    Secretary, Vice President & General Counsel

Key Competitors

View All Competitors

MRVFF Stock Analysis - Frequently Asked Questions

How have MRVFF shares performed in 2024?

Nuvo Pharmaceuticals' stock was trading at $0.9795 on January 1st, 2024. Since then, MRVFF shares have increased by 0.0% and is now trading at $0.9795.
View the best growth stocks for 2024 here.

How do I buy shares of Nuvo Pharmaceuticals?

Shares of MRVFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MRVFF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
The #1 Crypto for 2024
InvestorPlace